Hodgkin Disease

Andrea K Ng, Harvard Medical School, Boston, Massachusetts, USA
Peter M Mauch, Harvard Medical School, Boston, Massachusetts, USA

Published online: April 2001

DOI: 10.1038/npg.els.0002170

Hodgkin disease is a malignancy of the lymphatic system, affecting predominantly young adults. Advances in diagnosis, staging and treatment in the last 30 years have allowed long-term cure in the majority of patients. Current challenges include better understanding of the aetiology and pathophysiology of the disease, optimization of control rates especially in patients with unfavourable prognosis or advanced-stage disease, modification of therapeutic approaches to reduce the risk of long-term complications, and increasing the awareness of patients and physicians of the potential late effects of treatment so that patients can receive appropriate follow-up care.

Keywords: Hodgkin disease; lymphoma; Reed–Sternberg cells; radiation therapy; chemotherapy

 References
    Biti GP, Cimino G, Cartoni C et al. (1992) Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathological-stage I–IIA Hodgkin's disease: 8-year update of an Italian prospective randomized study. Journal of Clinical Oncology 10: 378–382.
    Cella D and Tross S (1986) Psychological adjustment to survival for Hodgkin's disease. Journal of Consulting and Clinical Psychology 54: 616–622.
    Constine L, Schwartz R, Savage D et al. (1997) Cardiac function, perfusion and morbidity in irradiated long-term survivors of Hodgkin's disease. International Journal of Radiation Oncology, Biology, Physics 39: 897–906.
    Cosset J, Henry-Amar M and Meerwaldt J (1991) Long-term toxicity of early stage of Hodgkin's disease therapy: the EORTC experience. Annal of Oncology 2(supplement 2): 77–82.
    Hancock S, Hoppe R, Horning S et al. (1988) Intercurrent death after Hodgkin's disease therapy in radiotherapy and adjuvant MOPP trials. Annals of Internal Medicine 109: 183–189.
    Hancock S, Tucker M and Hoppe R (1993) Breast cancer after treatment of Hodgkin's disease. Journal of the National Cancer Institute 85: 25–31.
    Harris NL, Jaffe ES, Diebold J et al. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting – Airlie House, Virginia, Novermber 1997. Journal of Clinical Oncology 17: 3835–3849.
    Harris NL, Jaffe ES, Stein H et al. (1994) A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Journal of Clinical Oncology 84: 1361–1392.
    Henry-Amar M and Somers R (1990) Survival outcome after Hodgkin's disease: a report from the International Data Base on Hodgkin's disease. Seminars in Oncology 17: 758–768.
    Loeffler M, Brosteanu O, Hasenclever D et al. (1998) Meta-analysis of chemotherapy versus combined modality therapy trials in Hodgkin's disease. Journal of Clinical Oncology 16: 818–829.
    Longo DL, Glatstein E, Duffey PL et al. (1991) Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: 7-year results of a prospective randomized trial. Journal of Clinical Oncology 9: 906–917.
    Mauch P, Kalish L, Marcus K et al. (1995) Long-term survival in Hodgkin's disease: relative impact of mortality, secondary tumor, infection and cardiovascular disease. Cancer Journal from Scientific American 1: 33–42.
    Nadali G, Vinante F, Ambrosetti A et al. (1994) Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. Journal of Clinical Oncology 12: 793–797.
    Specht L, Gray K, Clarke M et al. (1998) Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a metaanalysis of 23 randomized trials involving 3888 patients. Journal of Clinical Oncology 16: 830–843.
    Tubiana M, Henry-Amar M, Carde P et al. (1989) Toward comprehensive management tailored to prognostic factors of patients with clinical stages of I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964–1987. Blood 73: 47–56.
    van Leeuwen F, Klokman W, Stovall M et al. (1995) Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. Journal of the National Cancer Institute 87: 1530–1537.
    van Rijswijk R, Verbeek J, Haanen C et al. (1987) Major complications and causes of death in patients treated for Hodgkin's disease. Journal of Clinical Oncology 5: 1624–1633.
    Vaughan Hudson B, Vaughan Hudson G, Linch D et al. (1994) Late mortality in young British National Lymphoma Investigation patients cured of Hodgkin's disease. Annals of Oncology 5: 565–566.
    Wu T, Mann R, Charache P et al. (1990) Detection of Epstein–Barr virus messenger RNA in Reed–Sternberg cells of Hodgkin's disease. International Journal of Cancer 46: 801–804.
    Yahalom J, Petrek J, Biddinger P et al. (1992) Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathological analysis of 45 events in 37 patients. Journal of Clinical Oncology 10: 1674–1681.
 Further Reading
    book DeVita VT, Mauch PM and Harris NL (1997) "Hodgkin's disease". In: DeVita VT et al. (eds) Cancer: Principle and Practice of Oncology. London: Lippincott Williams and Wilkins.
    Jaffe E (1999) Hodgkin's lymphoma. Seminars in Hematology 36(3): 220–323.
    book Mauch PM, Armitage JO, Diehl V et al. (1999) Hodgkin's Disease. London: Lippincott Williams and Wilkins.

Related Sub-Topics:

Diagnostics, Therapeutics and Methods | Tumour Immunology | Cell Biology of Cancer
Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

Article Title: Hodgkin Disease
 
How to Cite close
Ng, Andrea K, and Mauch, Peter M(Apr 2001) Hodgkin Disease. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1038/npg.els.0002170]